Anteris Technologies Global (AVR) vs Cytek Biosciences (CTKB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anteris Technologies Global (AVR) has outperformed Cytek Biosciences (CTKB) over the past year, gaining 38.7% versus a gain of 37.4%. Cytek Biosciences is the larger company by market cap ($705.8 million vs $659.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVR | CTKB |
|---|---|---|
| Share price | $6.77 | $5.43 |
| Market cap | $659.79M | $705.81M |
| 1-day change | +2.11% | +1.31% |
| YTD return | +32.87% | +6.14% |
| 1-year return | +38.70% | +37.44% |
| 5-year return | — | -77.73% |
| Forward P/E | — | 77.57 |
| EPS (TTM) | $-1.95 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.06 | $6.21 |
| 52-week low | $3.30 | $3.31 |
| Distance from 52-week high | -38.76% | -12.56% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +106.79% | +2.39% |
| Average volume | 935.07K | 1.05M |
| Shares outstanding | 97.46M | 129.98M |
| Employees | 174 | 682 |
| Sector | Health Care | Industrials |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Anteris Technologies Global in Health Care and Cytek Biosciences in Industrials.
About Anteris Technologies Global
AVR stock →Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Health Care · Industrial Specialties · 174 employees
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
AVR vs CTKB FAQ
Which is bigger, Anteris Technologies Global or Cytek Biosciences?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $705.81M compared with $659.79M for Anteris Technologies Global (AVR).
Which stock has performed better over the past year, AVR or CTKB?
AVR returned +38.70% over the past 12 months, compared with +37.44% for CTKB (price return, excluding dividends). Past performance does not predict future results.
Are Anteris Technologies Global and Cytek Biosciences in the same industry?
No. Anteris Technologies Global is in the Health Care sector, while Cytek Biosciences is in Industrials.